ReviewBrain pathology (Zurich, Switzerland)2005
Angiogenesis in gliomas: imaging and experimental therapeutics.
Review in Brain pathology (Zurich, Switzerland), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 54 citations in OpenAlex.
- Clinical utility of GAL-8, ITGΒ-1, and HIF-1α as non-invasive diagnostic and prognostic biomarkers for assessing glioma.Journal of neuro-oncology · 2025Article
- Cell-Based Nanoparticles Delivery Systems for Targeted Cancer Therapy: Lessons from Anti-Angiogenesis Treatments.Molecules (Basel, Switzerland) · 2020Review
- Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far.International journal of nanomedicine · 2019Review
- Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.Clinical neuroradiology · 2018Article
- Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation.AJNR. American journal of neuroradiology · 2017Article
- Glioblastoma, hypoxia and autophagy: a survival-prone 'ménage-à-trois'.Cell death & disease · 2016Review
- Immune phenotypes predict survival in patients with glioblastoma multiforme.Journal of hematology & oncology · 2016Article
- OKN-007 decreases VEGFR-2 levels in a preclinical GL261 mouse glioma model.American journal of nuclear medicine and molecular imaging · 2015Article
- Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity.Scientific reports · 2014Article
- Quantification of tumor vessels in glioblastoma patients using time-of-flight angiography at 7 Tesla: a feasibility study.PloS one · 2014Article
- Molecular MRI of VEGFR-2 reveals intra-tumor and inter-tumor heterogeneity.American journal of nuclear medicine and molecular imaging · 2013Article
- Calpain 2 is required for the invasion of glioblastoma cells in the zebrafish brain microenvironment.Journal of neuroscience research · 2012Article
- Characterization of a human tumorsphere glioma orthotopic model using magnetic resonance imaging.Journal of neuro-oncology · 2011Article
- Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects.NMR in biomedicine · 2011Article
- Article
- EGFR gene overexpression retained in an invasive xenograft model by solid orthotopic transplantation of human glioblastoma multiforme into nude mice.Cancer investigation · 2011Article
- Galectins and gliomas.Brain pathology (Zurich, Switzerland) · 2010Review
- Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.Journal of oncology · 2010Article
- Characterization of tumor angiogenesis in rat brain using iron-based vessel size index MRI in combination with gadolinium-based dynamic contrast-enhanced MRI.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2009Article
- Antiangiogenic strategies for treatment of malignant gliomas.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Much of the interest in angiogenesis and hypoxia has led to investigating diagnostic imaging methodologies and developing efficacious agents against angiogenesis in gliomas. In many ways, because of the cytostatic effects of these agents on tumor growth and tumor-associated endothelial cells, the effects of therapy are not immediately evident. Hence finding clinically applicable imaging tools and pathologic surrogate markers is an important step in translating glioma biology to therapeutics. There are a variety of strategies in the approach to experimental therapeutics that target the hypoxia-inducible factor pathway, the endogenous antiangiogenic and proangiogenic factors and their receptors, adhesion molecules, matrix proteases and cytokines, and the existing vasculature. We discuss the rationale for antiangiogenesis as a treatment strategy, the preclinical and clinical assessment of antiangiogenic interventions and finally focus on the various treatment strategies, including combining antiangiogenic drugs with radiation and chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.